Phase <scp>I</scp>b/<scp>II</scp> study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan (<scp>JK1201I</scp>) as second‐line monotherapy for patients with small‐cell lung cancer
JK1201I exhibits promising efficacy and relatively low toxicities as a second-line monotherapy for SCLC, warranting further large-scale clinical studies to evaluate its efficacy in greater detail.
Authors
- Yanqiu Zhao (ORCID: https://orcid.org/0009-0009-8085-2302)
- Guohua Yu (ORCID: https://orcid.org/0009-0003-3441-0876)
- Xuan Zhao (ORCID: https://orcid.org/0000-0002-3135-8342)
- Jinsheng Shi (ORCID: https://orcid.org/0000-0003-2219-5956)
- Jian Fang (ORCID: https://orcid.org/0000-0002-1077-3686)
- Aimin Zang (ORCID: https://orcid.org/0000-0003-1681-831X)
- Lin Wu (ORCID: https://orcid.org/0000-0001-7078-7767)
- Xuefei Li (ORCID: https://orcid.org/0000-0003-0188-5667)
- Jieran Long
- Ligong Nie
Institutions
- Peking University (CN)
- Peking University Cancer Hospital (CN)
- Weifang People's Hospital (CN)
- People's Hospital of Cangzhou (CN)
- Hunan Cancer Hospital (CN)
- Peking University First Hospital (CN)
- Affiliated Hospital of Hebei University (CN)
- Henan Cancer Hospital (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1002/cam4.70059
- Citations
- 2
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.57